Navigation Links
Neurocrine Biosciences Reports Second Quarter 2012 Results

SAN DIEGO, July 31, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended June 30, 2012. For the second quarter of 2012, the Company reported a net loss of $0.5 million, or $0.01 loss per share, compared to net income of $2.0 million, or $0.04 per share, for the same period in 2011. For the six months ended June 30, 2012, the Company reported a net loss of $1.4 million, or $0.02 loss per share, as compared to net income of $4.9 million, or $0.09 per share, for the first half of last year.

The Company's balance sheet at June 30, 2012 reflected cash, cash equivalents, investments and receivables under collaboration agreements of $194.7 million compared to $203.2 million at March 31, 2012. 

"The elagolix program achieved a significant milestone this past quarter with the start of Phase III studies in endometriosis," said Kevin Gorman, Ph.D., President and Chief Executive Officer of Neurocrine Biosciences. "This coupled with the continued progress of elagolix in the Phase II uterine fibroids study, preparations for the VMAT2 Phase IIb program which is on track to start in August, and advancements in early research programs served for a very productive quarter."

Revenues for the second quarter of 2012 were $10.6 million, compared to $12.2 million for the same period in 2011. Revenues for the six months ended June 30, 2012 were $21.8 million, compared to $24.7 million for the first half of 2011. The decrease in revenue from 2011 to 2012 is due to lower revenue recognition under the collaboration agreement with Abbott for our GnRH program, as substantially all of the workload for elagolix was transferred to Abbott.

During the second quarter and six months ended June 30, 2012 the Company recognized $1.2 million and $2.6 million, respectively, in revenue from internal and external research and development expense reimbursement under its Abbott collaboration agreement. This compares to internal and external research and development expense reimbursement revenue from Abbott of $2.5 million and $5.4 million during the second quarter of 2011 and six months ended June 30, 2011, respectively.

Research and development expenses were $8.8 million during the second quarter of 2012 compared to $8.2 million for the same period in 2011. For the six months ended June 30, 2012, research and development expenses were $18.2 million, compared to $15.5 million for the same period last year. The increase in research and development expenses is primarily due to increased personnel related costs and share-based compensation expense. Additionally, higher year-to-date external development costs related to the VMAT2 program were partially offset by a decrease in elagolix external development expenses as a result of the continued transition of elagolix development work to Abbott.

General and administrative expenses were $3.1 million for the second quarter of 2012 and $2.8 million during the same period last year. For the six months ended June 30, 2012, general and administrative expenses were $6.8 million, compared to $6.0 million for the first half of 2011. The increase in general and administrative expenses is primarily due to higher share-based compensation expense.

Pipeline HighlightsElagolix UpdateAbbott launched the initial Phase III study during the second quarter of 2012. The study is a 24-week, multinational, randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of elagolix in 875 women, age 18 to 49, with moderate-to-severe endometriosis-associated pain. The initial Phase II study is currently being conducted at approximately 160 sites in the United States, Puerto Rico and Canada.

Abbott is conducting a Phase II study of elagolix in uterine fibroids to assess blood loss in women with heavy uterine bleeding due to such fibroids.

VMAT2 UpdateThe Company is moving its VMAT2 inhibitor, NBI-98854, into Phase IIb clinical trials.  An investigator meeting will be held in early August for a large Phase IIb trial which will begin screening in the third quarter of 2012. This placebo-controlled, double-blind, parallel design, multiple dose, 12 week study will assess six week dosing of NBI-98854, against placebo, followed by six weeks of active treatment with NBI-98854. The study will also incorporate a capsule formulation of NBI-98854. Top-line data from this study is expected in the first quarter of 2013.

Conference Call and Webcast Today at 5:00PM Eastern Time
Neurocrine will hold a live conference call and webcast today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Participants can access the live conference call by dialing 800-862-9098 (US) or 785-424-1051 (International) using the conference ID: NBIX. The call can also be accessed via the webcast through the Company's website at

If you are unable to attend the webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at A replay of the conference call will be available approximately one hour after the conclusion of the call by dialing 800-695-0671 (US) or 402-220-1397 (International) using the conference ID: NBIX. The call will be archived for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine-related diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, pain, tardive dykinesia, uterine fibroids, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's R & D pipeline and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's R & D pipeline include risk that the ongoing Phase III endometriosis clinical trial for elagolix, the  most advanced clinical program in the Company's pipeline, will fail to support the additional Phase III clinical trial required for regulatory approval; risk that the elagolix Phase III program overall will encounter delays for regulatory or other reasons; risk that the elagolix Phase III clinical program will fail to demonstrate that elagolix is safe and effective for the treatment of endometriosis or support filings for regulatory approval; risk that the uterine fibroid elagolix clinical trials will fail to demonstrate that elagolix is safe and effective for the treatment of uterine fibroids; and  risks associated with the Company's dependence on corporate collaborators for Phase III development, commercial manufacturing and marketing and sales activities. In addition, the Company faces risks and uncertainties with respect to the rest of the Company's R & D pipeline including risk that the Company's clinical candidates will not be found to be safe and effective; risk that the Company's VMAT2 clinical candidates will not proceed to later stage clinical trials; and risk that the Company's research programs will not identify pre-clinical candidates for further development. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2011 and report on Form 10-Q for the quarter ended March 31, 2012. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.

 NEUROCRINE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share data)(unaudited)Three Months Ended
June 30,Six Months Ended
June 30,2012201120122011Revenues:Sponsored research and development 




,193Milestones and license fees9,029



18,476Total revenues10,569



24,669Operating expenses:Research and development8,818



15,493General and administrative3,131



5,965Cease-use expense-



176Total operating expenses11,949



21,634(Loss) income from operations(1,380)



3,035Other income:Gain on sale/disposal of assets-



98Deferred gain on real estate759



1,473Investment income, net115



239Other income, net5



13Total other income879



1,823Net (loss) income



$ (1,387)

Net (loss) income per common share:Basic$   (0.01)


$   (0.02)

Diluted$   (0.01)


$   (0.02)

Shares used in the calculation of net (loss) income per common share:Basic66,309






56,276 NEUROCRINE BIOSCIENCES, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands)(unaudited)June 30, 2012December 31,
2011Cash, cash equivalents and short-term marketable securities


29,103Other current assets


3,373Total current assets


132,476Property and equipment, net


1,586Long-term investments


—Restricted cash


4,306Total assets


Current liabilities


47,110Long-term liabilities


31,177Stockholders' equity


60,081Total liabilities and stockholders' equity





SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
2. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
3. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
4. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
5. Amarantus BioSciences Corporate Overview to be Webcast Live Today from OneMedForum 2012 Conference in NYC
6. Pressure BioSciences, Inc. Continues Global Sales Reach Expansion with Distribution Agreements for China, Vietnam, Laos, Cambodia, Australia, and New Zealand
7. Interviews Amarantus BioSciences President & CEO Gerald E. Commissiong
8. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
9. Pressure BioSciences, Inc. Reaches Agreement with Investors on Initial $600,000 Tranche of $1.2 Million Above-Market Private Placement; Proceeds to Support Continued Commercialization of PCT Product Platform
10. Amarillo Biosciences Announces Plan to Open Asia Operations Center in Taipei, Taiwan
11. Tanke BioSciences To Host Leading Symposium On Food Safety, June 24-25
Post Your Comments:
(Date:10/8/2015)... 2015 .   ... Goldman Small Cap Research, a stock market ... microcap sectors, announced today that it has published ... Inc. (OTCQB - PMCB), a publicly traded, clinical ... treatments for cancer and diabetes. To view the ...
(Date:10/8/2015)...  The ALS Association, in partnership with Prize4Life, is ... revolutionize communication technology solutions for people living with ALS. ... (amyotrophic lateral sclerosis) is a progressive neurodegenerative disease that ... spinal cord. Eventually, people with ALS lose the ability ... to total paralysis and death within two to five ...
(Date:10/8/2015)... ... , ... Talon Innovations, a provider of Precision Machined Products and ... is one of three finalists for the Minnesota Business magazine’s Manufacturing Award in the ... Innovations was recognized as a nominee for this competitive award. , The “Best ...
(Date:10/7/2015)... , Oct. 7, 2015 Boston ... the start of the Boston Scientific Connected Patient ... advancements in the use of remote patient monitoring to ... designers and entrepreneurs can submit their ideas and collaborate ... ( ). Cambridge, MA ...
Breaking Biology Technology:
... PARK, N.C., Nov. 16, 2010 Scientists from ... data demonstrating that the company,s lipid-conjugated drugs, CMX001 ... Organic Anion Transporters (hOATs) and thus have significantly ...  These data, presented at the International Pharmaceutical Federation ...
... has announced the winners of its 2010 Photo Prize ... and Mario Pereda from Spain were awarded first, second ... respectively. The winning photos were selected from 3800 entries, ... interpretation of Syngenta,s purpose: Bringing plant potential to life. ...
... announces that a new market research report ... Global Specialty Enzymes Industry ... worldwide markets for Specialty Enzymes in US$ Million ... Enzymes, Polymerases, Nucleases, and Other Specialty Enzymes. The ...
Cached Biology Technology:
(Date:9/28/2015)... Calif. , Sept. 28, 2015 Synaptics ... human interface solutions, today announced that Lenovo has selected ... fingerprint sensor, FS4202, for its latest smartphone, the Vibe ... password-free access to unlock the device and provide swift ... The feature-rich Natural ID FS4202 sensor solution ...
(Date:9/10/2015)... , Sept. 10, 2015 Report Details ... Study Reveals Selling Opportunities and Revenue Prospects to ... future of biologics, especially new drug classes? Get ... stay ahead with exclusive market data and industry ... trends, developments, results, opportunities and sales predictions. ...
(Date:9/8/2015)... AUSTIN, Texas , Sept. 8, 2015   ... results of the new survey, Smart Marketing for ... survey of 580 engineering professionals reveals insightful findings about ... as the types of content engineers most value and ... Marketers targeting technical audiences grapple with ...
Breaking Biology News(10 mins):
... representing solar industry stakeholders has developed standard contracts that ... to access low-cost financing for residential and commercial solar ... (SAPC) working group, assembled by the Energy Department,s National ... developers, law firms, financiers and analysts with expertise in ...
... Cold Spring Harbor Laboratory (CSHL) today announced the launch of ... -- a new, free service, called bioRxiv (pronounced "bio-Archive"). ... share the results of their work before peer review and ... its contents costs nothing. Each paper is given a ...
... DETROIT Collaborating with researchers from the Northwestern University ... at Wayne State University,s School of Medicine led by ... in the inflammatory stress mechanism and specific inhibitor for ... by Zhang, associate professor of immunology and microbiology and ...
Cached Biology News:
... human XAB2 (amino terminus) XAB2 (XPA-binding ... interaction with XPA. Immunoprecipitation experiments have also ... with the transcription-coupled repair-specific proteins CSA and ... II. Microinjection experiments with XAB2 antibodies resulted ...
... maintenance, calibration, and validation (MCV) ... 96-well plate used for hands-free ... procedures using the Bio-Plex suspension ... is for use with Bio-Plex ...
Biology Products: